Chmn Rachman Buys 746 ($5K) Of Immix Biopharma Inc [IMMX]

Rachman Ilya M Chairman of the Board of Immix Biopharma Inc [IMMX] filed a Form 4 on December 10, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/10/25TransactionPurchaseShares746Price$6.67Value$4,976Ending Holdings: 1,141,683 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Immix Biopharma CFO Gabriel S. Morris Reports Acquisition of Common Shares

Gabriel S. Morris, CFO and Director of Immix Biopharma Inc., reported acquiring common shares of the company. The information was published via EDGAR by the U.S. SEC on December 10, 2025. This news brief was generated by Public Technologies using AI and is for informational purposes only.

Immix Biopharma shares are trading higher after HC Wainwright & Co. raised the price target from $8 to $12.

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | IMMX Stock News

Immix Biopharma announced the closing of a $100 million underwritten offering of common stock and pre-funded warrants, raising approximately $93.7 million after expenses. The offering included leading U.S. biotechnology institutional investors and mutual funds. Morgan Stanley acted as the sole book-running manager, with Citizens Capital Markets and Mizuho as co-managers. The offering was conducted under a shelf registration statement filed with the SEC. Immix Biopharma is a leader in relapsed/refractory AL Amyloidosis treatment.

Immix Biopharma Enters Underwriting Agreement with Morgan Stanley

Immix Biopharma has entered an underwriting agreement with Morgan Stanley to issue over 19 million shares, priced at $5.10 each, aiming to raise approximately $93.7 million. The closing is expected on December 9, 2025. This move is part of a strategy to strengthen the company's capital and enhance its market position. Analysts rate IMMX stock as a Buy with a $8.00 price target.